The privately owned IRBM Group, a diversified industrial group operating within the biotech and pharmaceutical sector, is composed by IRBM, IRBM PROMIDIS, Advent and the CNCCS Consortium. IRBM is a the parent company dedicated to innovative preclinical drug discovery and development in areas of high unmet medical need, including neurodegenerative and rare and neglected diseases.
We are your “one-stop-shop” for all your preclinical drug development needs.
Our team of experienced scientists has a proven track record.
Areas of particular expertise include fully integrated small molecule and peptide-based drug discovery, peptide-based vaccines, ADMET optimization and biomarker development.
In particular we relish the challenge of poorly druggable targets.